Clinical deterioration following improvement in the NINDS rt-PA stroke trial

Stroke

Volumn 32, Issue 3, 2001, Pages

  Grotta, J C ^a   Welch, K M A ^a   Fagan, S C ^a   Lu, M ^a   Frankel, M R ^a   Brott, T ^a   Levine, S R ^a   Lyden, P D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Deterioration; Reocclusion; Stroke; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRIN DEGRADATION PRODUCT; GLUCOSE; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; HEALTH CARE ORGANIZATION; HOSPITALIZATION; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK; STATISTICAL MODEL; UNITED STATES;

CEREBROVASCULAR ACCIDENT; DISEASE PROGRESSION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NATIONAL INSTITUTES OF HEALTH (U.S.); ODDS RATIO; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 0034745236     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.32.3.661     Document Type: Article

References (28)

1. Thresholds of focal cerebral ischemia in awake monkeys
2. Tissue plasminogen activator: Reduction of neurologic damage after experimental embolic stroke
3. Urgent therapy for stroke: 1, pilot study of tissue plasminogen activator administered within 90 minutes
4. Urgent therapy for stroke: II, pilot study of tissue plasminogen activator administered 91-180 minutes from onset
5. Clinical and instrumental evaluation of patients with ischemic stroke within the first 6 hours
6. Tissue plasminogen activator for acute ischemic stroke
7. t-PA-associated reperfusion after acute stroke demonstrated by SPECT
8. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke
9. Generalized efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS t-PA Stroke Trial
10. Rethrombosis after successful thrombolysis of the vertebrobasilar system
11. "Spectacular shrinking deficit:" Rapid recovery from a major hemispheric syndrome by migration of an embolus
12. Deterioration following spontaneous improvement: Sonographic findings in patients with acutely resolving symptoms of cerebral ischemia
13. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
14. The significance of clinical deterioration in acute carotid distribution cerebral infarction
15. Neurological deterioration in acute ischemic stroke: Potential predictors and associated factors in the European Cooperative Acute Stroke Study (ECASS) I
16. Hypertension and its treatment in the NINDS rt-PA stroke trial
17. The ischemic penumbra, injury thresholds, and the therapeutic window for acute stroke
18. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging
19. Reperfusion injury: Demonstration of brain damage produced by reperfusion after transient focal ischemia in rats
20. The international stroke trial (1ST): A randomized trial, of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke
21. CAST: Randomized placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke
22. Does platelet antiaggregant therapy lessen the severity of stroke?
23. Effect of blood pressure and diabetes on stroke in progression
24. Deteriorating ischemic stroke: Risk factors and prognosis
25. Progressing neurological deficit secondary to acute ischemic stroke: A study on predictability, pathogenesis, and prognosis
26. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke
27. Hemostatic markers in acute ischemic stroke: Association with stroke type, severity, and outcome
28. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator